

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Hangzhou Diagens Biotechnology Co., Ltd.

杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2526)

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 2026 second extraordinary general meeting (the “**EGM**”) of Hangzhou Diagens Biotechnology Co., Ltd. (the “**Company**”) will be held at Conference Room 1, 9th Floor, Building A, No. 609, Hongfeng Road, Linping District, Hangzhou, Zhejiang, PRC on Wednesday, September 30, 2026 at 10:00 a.m. for the Shareholders to consider and, if thought fit, approve the following resolutions of the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated September 10, 2026 (the “**Circular**”):

SPECIAL RESOLUTIONS

1. To consider and, if thought fit, pass with or without amendments, the following resolution as a special resolution:

“**THAT** subject to and conditional upon the Listing Committee of the Stock Exchange granting approval of the listing of, and permission to deal in, the shares of the Company (not exceeding 10% of the Company’s issued share capital on the date of this resolution) which may fall to be issued under the 2026 Share Incentive Scheme, the rules of which are contained in the document marked “A” produced to the meeting and signed by the chairman of the meeting for identification purposes or other schemes of the Company, the 2026 Share Incentive Scheme be and is hereby approved and adopted and the Board or its Delegate(s) be and are hereby authorized to grant Share Awards and to allot, issue and deal with the shares which fall to be issued under the 2026 Share Incentive Scheme and to take all such steps as may be necessary or expedient in order to give full effect to the 2026 Share Incentive Scheme including, but not limited to:

- (a) interpret and construe the provisions of the 2026 Share Incentive Scheme;
- (b) determine the persons who will be granted Share Awards under the 2026 Share Incentive Scheme;
- (c) the terms and conditions on which Share Awards are granted and when the RSUs granted pursuant to the 2026 Share Incentive Scheme may vest;

- (d) determine how the Exercise Price will be settled;
 - (e) allot and issue new Shares to the Trustee to hold, for the purpose of fulfilling delivery obligations upon the vesting of Share Awards;
 - (f) direct and arrange for the Trustee to purchase existing H Shares (which may be made on-market or off-market) for the purpose of fulfilling delivery obligations upon the vesting of Share Awards (the Company shall ensure that sufficient funds are provided to the Trustee by any means determined by the Board to enable it to fulfill its obligations related to the administration of this 2026 Share Incentive Scheme);
 - (g) without prejudice to the foregoing, whether the H Shares underlying the Share Awards are acquired through secondary market purchases or, fulfilled by the use of Treasury Shares or by subscription for new H Shares shall be determined by the Board, taking into consideration comprehensive factors such as the Company's financial condition, cash position, and the prevailing market price of the H Shares at the relevant time;
 - (h) make such other decisions or determinations as it shall deem appropriate in the administration of the 2026 Share Incentive Scheme; and
 - (i) on behalf of the Company, approve, execute, amend, deliver, negotiate, agree on and agree to all such agreements, contracts, documents, regulations, matters and things (as the case may be) as it deems reasonable, necessary, desirable, appropriate or expedient, in order to implement and/or give effect to all transactions conducted accordingly, and make any reasonable alterations, amendments, changes, modifications and/or supplements as it deems necessary, desirable, appropriate or expedient. If there is a requirement to affix a company seal on any such agreement, contract or document, it has the right to sign the agreement, contract or document and affix the company seal in accordance with the Articles of Association in that case."
2. **"THAT**, the limit on the total number of shares of the Company that may be issued in respect of all options and awards involving issue of new H Shares (including the Shares to be allotted and issued using Treasury Shares) to be granted under the 2026 Share Incentive Scheme and any other share scheme(s) of the Company (the **"Scheme Mandate Limit"**) of 10 per cent. (10%) of the total number of Shares of the Company in issue (excluding Treasury Shares and rounded to the nearest whole share) on the date of adoption of the 2026 Share Incentive Scheme be and is hereby approved and adopted, and any directors of the Company be and is hereby authorized to take all such steps and attend all such matters, approve and execute (whether under hand under seal) such documents and do such other things, for and on behalf of the Company, as he may in his absolute discretion consider necessary, desirable or expedient to effect and implement the Scheme Mandate Limit."

3. “**THAT**, within the Scheme Mandate Limit, the total number of Shares which may be issued in respect of all awards and options (if any) involving issue of new H Shares that may be granted under the 2026 Share Incentive Scheme and any other share scheme(s) (if any) of the Company to the Service Providers must not in aggregate exceed 2% of the total number of Shares in issue as at the date of adoption (excluding Treasury Shares and rounding to the nearest whole Share) (the “**Service Provider Sublimit**”).”

By Order of the Board

Hangzhou Diagens Biotechnology Co., Ltd.

Song Ning

Chairman of the Board, Executive Director and General Manager

Hangzhou, PRC, September 10, 2026

Notes:

1. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the articles of association of the Company and the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange (www.hkexnews.hk) and of the Company (www.diagens.com) in accordance with the Listing Rules.
2. For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Friday, September 25, 2026 to Wednesday, September 30, 2026, both dates inclusive, during which period no transfer of Shares will be registered. The record date for determining the identity of the Shareholders who are entitled to attend and vote at the EGM is Friday, September 25, 2026. In order to be eligible to attend and vote at the EGM, holders of the H Shares whose transfers have not been registered shall deposit all transfer documents accompanied by the relevant share certificates at the Company’s H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, for registration not later than 4:30 p.m. on Thursday, September 24, 2026 (Hong Kong time) for registration.
3. A Shareholder entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on his/her behalf. A proxy need not be a Shareholder of the Company. Where a Shareholder appoints more than one proxy, his/her proxies can only vote on a poll. For the avoidance of doubt and for the purposes of the Listing Rules, holders of Treasury Shares (if any) are not entitled to vote at the Company’s general meetings.
4. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his/her attorney duly authorised. If the Shareholder is a corporation, that instrument must be either under its common seal or under the hand of its director(s) or duly authorised attorney(ies). If that instrument is signed by an attorney of a Shareholder, the power of attorney or other document authorising that attorney to sign must be notarised.

In order to be valid, the form of proxy together with the notarised power of attorney or other authorisation document (if any) must be deposited at the H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong not less than 24 hours before the time fixed for the meeting (i.e. not later than 10:00 a.m. on Tuesday, September 29, 2026 (Hong Kong time)). Completion and return of the form of proxy will not preclude a Shareholder from attending and voting at the EGM or any adjourned meeting thereof should he/she so wish.

5. A vote given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the death or loss of capacity of the appointer, or the revocation of the proxy or of the authority under which the form of proxy was signed, or the transfer of shares in respect of which the proxy is given, provided that no notice in writing of these matters shall have been received by the Company prior to the commencement of the EGM.
6. In case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
7. Shareholders or their proxies shall produce their identification documents for inspection when attending the EGM. If a corporate Shareholder appoints an authorized representative to attend the EGM, the authorized representative shall produce his/her identity documents and a notarial certified copy of the relevant authorization instrument signed by the board of directors, director(s), legal representative, or other authorized parties of the corporate Shareholder or other notarial certified documents allowed by the Company. Proxies shall produce their identity documents and the form of proxy signed by the Shareholders or their attorney when attending the EGM.
8. The EGM is expected to last for no more than half of a working day. Shareholders and their proxies attending the meeting shall be responsible for their own traveling and accommodation expenses.
9. References to dates and time in this notice are to Hong Kong dates and time.
10. Designated contact for the EGM:

Telephone No.: +86 153 9707 8765

Attention: Wu Chengfa

As of the date of this notice, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors, (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors, and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.